Artera AI

AI oncology platform predicting treatment outcomes from pathology slides to guide personalized therapy.

Best for: Reduces unnecessary treatment Not ideal for: Narrow cancer type focus
Price Paid
Free plan No
For Business teams
Level Beginner
Updated Mar 2026
Category Healthcare AI
Share Twitter LinkedIn
01

Why choose Artera AI

Artera (formerly ArteraAI) is an AI platform for treatment outcome prediction in oncology. Its multimodal AI analyzes digital pathology slides and clinical data to predict which cancer patients will respond to specific treatments — helping oncologists avoid over-treatment and personalize therapy decisions with hard clinical evidence.

  • +Reduces unnecessary treatment
  • +Strong clinical evidence
  • +Trusted by academic oncology centers
  • +FDA breakthrough pathway
02

Where it falls short

  • Narrow cancer type focus
  • Enterprise sales cycle
  • Not yet widely available
03

Best for these users

👤
Target audience
Business teams, knowledge workers
📌
Best for
Reduces unnecessary treatment
Skip if you need
Narrow cancer type focus
04

Pricing overview

Paid Free plan: No

Laboratory and health system pricing. Contact sales.

Check current pricing →
05

Key features

Treatment outcome prediction
Pathology slide analysis
Multimodal clinical data integration
Prostate and bladder cancer focus
Clinical trial biomarker analysis
FDA submission support
07

Alternatives to Artera AI

DeepMind AlphaFold

DeepMind's AI that predicts protein structures with atomic accuracy, transforming drug discovery.

Nuance DAX

Microsoft's ambient clinical AI that auto-generates structured notes from patient conversations.

Suki AI

AI voice assistant that automates clinical documentation for healthcare professionals.

Abridge

AI platform that records and summarizes clinical conversations for doctors and patients.

Aidoc

AI radiology platform that flags critical findings in medical imaging in real time.

See all alternatives →
08

Related comparisons

09

The verdict

Artera AI Paid

Artera AI is a solid choice for business teams who need reduces unnecessary treatment. At paid, it delivers good value. Main caveat: narrow cancer type focus. Compare with alternatives before committing.